ribociclib

Known as: 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide 
An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
020406020152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
  • Cancer discovery
  • 2018
Adding the CDK4/6 inhibitor ribociclib to standard first-line endocrine therapy significantly prolonged survival in premenopausal… (More)
Is this relevant?
2017
2017
To the Editor: In their interim analysis of the Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety… (More)
Is this relevant?
2017
2017
Ribociclib is an oral, small-molecule inhibitor of cyclin-dependent kinase (CDK) 4 and 6 that is under development by Novartis… (More)
Is this relevant?
2017
2017
The treatment landscape for advanced breast cancer has changed radically over the last 30–40 years with the refinement of… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2017
Review
2017
CDK4/6 inhibitors are a promising new class of drugs for hormone-receptor-positive breast cancer and have been shown to overcome… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2017
2017
Purpose: The cyclin-dependent kinase (CDK) 4/6 inhibitor, ribociclib (LEE011), displayed preclinical activity in neuroblastoma… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to… (More)
Is this relevant?
2016
2016
OBJECTIVES Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2016
2016
PURPOSE Ribociclib (an oral, highly specific cyclin-dependent kinase 4/6 inhibitor) inhibits tumor growth in preclinical models… (More)
Is this relevant?
2016
2016
  • Cancer discovery
  • 2016
The combination of antiestrogen therapy and ribociclib, an investigational CDK4/6 inhibitor, led to improved outcomes in women… (More)
Is this relevant?